New dosing strategy aims to help breast cancer patients stick with treatment
NCT ID NCT07599137
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 participants will be followed for 12 weeks to see how well they tolerate the step-up dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib (a targeted cancer drug)
What this could lead to
If successful, this step-up dosing approach could help more patients tolerate and complete their full course of abemaciclib, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase study (86 participants) focused on tolerability, not on proving the drug works better. Side effects like diarrhea and fatigue may still occur, and results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••